Vetmab Biosciences, Inc. — SEC Form D Filing
Vetmab Biosciences, Inc. filed an SEC Form D on September 29, 2026, reporting $11.44M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 29, 2026
- Amount reported
- $11.44M
- Round stage
- Series A, as an $11.4 million equity raise is the standard size for a biotechnology company advancing from preclinical research into veterinary clinical trials.
- Industry
- Biotechnology
- Website
- https://www.vetmab.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Companion animals suffering from chronic inflammatory, allergic, and oncological diseases lack targeted, species-specific biologic therapies, forcing veterinarians to rely on repurposed human drugs with severe side effects.
Solution
Vetmab Biosciences develops veterinary-specific monoclonal antibody therapeutics designed to safely and precisely target chronic diseases in pets.
Why now
The rising humanization of pets has driven unprecedented consumer demand and willingness to pay for premium, advanced veterinary healthcare solutions.
Verdict
This cleared because investors bet on the *de-risking potential* of a platform approach to animal biologics, not because a specific blockbuster drug was already in human trials. The implicit bet was on the ability to rapidly iterate and apply known antibody science to high-value veterinary indications, creating a diversified pipeline. This approach limited upside by introducing significant regulatory and market adoption hurdles for *multiple* distinct products, rather than concentrating capital on accelerating one high-conviction asset.
Source: SEC EDGAR Form D filing